scholarly journals Methylation Assay for the Diagnosis of Lung Cancer on Bronchial Aspirates: A Cohort Study

2005 ◽  
Vol 11 (21) ◽  
pp. 7728-7734 ◽  
Author(s):  
Viola Schmiemann ◽  
Alfred Böcking ◽  
Marietta Kazimirek ◽  
Alexandre Sherlley Casimiro Onofre ◽  
Helmut Erich Gabbert ◽  
...  
2016 ◽  
Vol 77 (12) ◽  
pp. e1626-e1630 ◽  
Author(s):  
Daniel W. Bradford ◽  
Joseph Goulet ◽  
Marcia Hunt ◽  
Natasha C. Cunningham ◽  
Rani Hoff

2015 ◽  
Vol 19 (3) ◽  
pp. 159-167 ◽  
Author(s):  
Lele Song ◽  
Haotian Yu ◽  
Yuemin Li

2020 ◽  
pp. bjgp20X713993
Author(s):  
Stephen H Bradley ◽  
Nathaniel Luke Fielding Hatton ◽  
Rehima Aslam ◽  
Bobby Bhartia ◽  
Matthew EJ Callister ◽  
...  

BackgroundChest X-ray (CXR) is the first-line investigation for lung cancer in many countries but previous research has suggested that the disease is not detected by CXR in approximately 20% of patients. The risk of lung cancer, with particular symptoms, following a negative CXR is not known.AimTo establish the sensitivity and specificity of CXR requested by patients who are symptomatic; determine the positive predictive values (PPVs) of each presenting symptom of lung cancer following a negative CXR; and determine whether symptoms associated with lung cancer are different in those who had a positive CXR result compared with those who had a negative CXR result.Design and settingA prospective cohort study was conducted in Leeds, UK, based on routinely collected data from a service that allowed patients with symptoms of lung cancer to request CXR.MethodSymptom data were combined with a diagnostic category (positive or negative) for each CXR, and the sensitivity and specificity of CXR for lung cancer were calculated. The PPV of lung cancer associated with each symptom or combination of symptoms was estimated for those patients with a negative CXR.ResultsIn total, 114 (1.3%) of 8996 patients who requested a CXR were diagnosed with lung cancer within 1 year. Sensitivity was 75.4% and specificity was 90.2%. The PPV of all symptoms for a diagnosis of lung cancer within 1 year of CXR was <1% for all individual symptoms except for haemoptysis, which had a PPV of 2.9%. PPVs for a diagnosis of lung cancer within 2 years of CXR was <1.5% for all single symptoms except for haemoptysis, which had a PPV of 3.9%.ConclusionCXR has limited sensitivity; however, in a population with a low prevalence of lung cancer, its high specificity and negative predictive value means that lung cancer is very unlikely to be present following a negative result. Findings also support guidance that unexplained haemoptysis warrants urgent referral, regardless of CXR result.


2019 ◽  
Vol 7 (3) ◽  
pp. 196-207
Author(s):  
Lev Utkin ◽  
Anna Meldo ◽  
Viktor Kryshtapovich ◽  
Viktor Tiulpin ◽  
Ernest Kasimov ◽  
...  

2017 ◽  
Vol 63 (6) ◽  
pp. 926-932
Author(s):  
Lyudmila Belskaya ◽  
Viktor Kosenok ◽  
Ж. Массард

So far optimization problems for diagnostics and prognostication aids remained relevant for lung cancer as a leader in the structure of cancers. Objective: a search for regularities of changes in the saliva enzyme activity in patients with nonsmall cell lung cancer. In the case-control study, 505 people took part, divided into 2 groups: primary (lung cancer, n=290) and control (conventionally healthy, n=215). All the participants went through a questionnaire survey, saliva biochemical counts, and a histological verification of their diagnosis. The enzyme activity was measured with spectrophotometry. Between-group differences were measured with the nonparametric test. It was shown that in terms of lung cancer, we observe metabolic changes, described with the decreased de Ritis coefficient (p


Sign in / Sign up

Export Citation Format

Share Document